The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Inhibition of Heparin-induced Tau Filament Formation by Phenothiazines, Polyphenols, and Porphyrins
Open accessAbstract
Tau protein is the major component of the intraneuronal filamentous inclusions that constitute defining neuropathological characteristics of Alzheimer's disease and other tauopathies. The discovery of tau gene mutations in familial forms of frontotemporal dementia has established that dysfunction of the tau protein is sufficient to cause neurodegeneration and dementia. Here we have tested 42 compounds belonging to nine different chemical classes for their ability to inhibit heparin-induced assembly of tau into filaments in vitro. Several phenothiazines (methylene blue, azure A, azure B, and quinacrine mustard), polyphenols (myricetin, epicatechin 5-gallate, gossypetin, and 2,3,4,2',4'-pentahydroxybenzophenone), and the porphyrin ferric dehydroporphyrin IX inhibited tau filament formation with IC(50) values in the low micromolar range as assessed by thioflavin S fluorescence, electron microscopy, and Sarkosyl insolubility. Disassembly of tau filaments was observed in the presence of the porphyrin phthalocyanine. Compounds that inhibited tau filament assembly were also found to inhibit the formation of Abeta fibrils. Biochemical analysis revealed the formation of soluble oligomeric tau in the presence of the inhibitory compounds, suggesting that this may be the mechanism by which tau filament formation is inhibited. The compounds investigated did not affect the ability of tau to interact with microtubules. Identification of small molecule inhibitors of heparin-induced assembly of tau will form a starting point for the development of mechanism-based therapies for the tauopathies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Metabolic and Molecular Bases of Inherited Disease
Scriver, R. C. (1995) · Medical Entomology and Zoology · Cited by 12,101
The metabolic and molecular bases of inherited disease
Chen, Y.-T. (2001) · Medical Entomology and Zoology · Cited by 6,928
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease
Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., et al. (1995) · Nature · doi:10.1038/375754a0 · Cited by 4,051
Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17
Hutton, M., Lendon, C. L., Rizzu, P., Baker, M., Froelich, S., Houlden, H., Pickering-Brown, S., Chakraverty, S., Isaacs, A., Grover, A., et al. (1998) · Nature · doi:10.1038/31508 · Cited by 3,498
Candidate gene for the chromosome 1 familial Alzheimer’s disease locus
Levy-Lahad, E., Wasco, W., Poorkaj, P., Romano, D. M., Oshima, J., Pettingell, W. H., Yu, C.-E., Jondro, P. D., Schmidt, S. D., Wang, K., et al. (1995) · Science · doi:10.1126/science.7638622 · Cited by 2,577
Goedert, M., Spillantini, M. G., Jakes, R., Rutherford, D., & Crowther, R. A. (1989) · Neuron · doi:10.1016/0896-6273(89)90210-9 · Cited by 2,492
Self-citationLee, V. M.-Y., Goedert, M., & Trojanowski, J. Q. (2001) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.24.1.1121 · Cited by 2,480
Self-citationRogaev, E. I., Sherrington, R., Rogaeva, E. A., Levesque, G., Ikeda, M., Liang, Y., Chi, H., Lin, C., Holman, K., Tsuda, T., et al. (1995) · Nature · doi:10.1038/376775a0 · Cited by 2,052
Mutation in the tau gene in familial multiple system tauopathy with presenile dementia
Spillantini, M. G., Murrell, J. R., Goedert, M., Farlow, M. R., Klug, A., & Ghetti, B. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.13.7737 · Cited by 1,474
Self-citationTau is a candidate gene for chromosome 17 frontotemporal dementia
Poorkaj, P., Bird, T. D., Wijsman, E., Nemens, E., Garruto, R. M., Anderson, L., Andreadis, A., Wiederholt, W. C., Raskind, M., & Schellenberg, G. D. (1998) · Annals of Neurology · doi:10.1002/ana.410430617 · Cited by 1,374
Lewis, J., McGowan, E., Rockwood, J., Melrose, H., Nacharaju, P., Van Slegtenhorst, M., Gwinn-Hardy, K., Murphy, M. P., Baker, M., Yu, X., et al. (2000) · Nature Genetics · doi:10.1038/78078 · Cited by 1,371
Kinetic Stabilization of the α-Synuclein Protofibril by a Dopamine-α-Synuclein Adduct
Conway, K. A., Rochet, J.-C., Bieganski, R. M., & Lansbury, P. T. (2001) · Science · doi:10.1126/science.1063522 · Cited by 1,127
Goedert, M., Jakes, R., Spillantini, M. G., Hasegawa, M., Smith, M. J., & Crowther, R. A. (1996) · Nature · doi:10.1038/383550a0 · Cited by 1,036
Self-citationWhat does it mean to be natively unfolded?
Uversky, V. N. (2002) · European Journal of Biochemistry · doi:10.1046/j.0014-2956.2001.02649.x · Cited by 982
X-RAY DIFFRACTION STUDIES ON AMYLOID FILAMENTS
EANES, E. D., & GLENNER, G. G. (1968) · Journal of Histochemistry & Cytochemistry · doi:10.1177/16.11.673 · Cited by 823
Neurodegenerative Diseases and Prions
Prusiner, S. B. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105173442006 · Cited by 772
Allen, B., Ingram, E., Takao, M., Smith, M. J., Jakes, R., Virdee, K., Yoshida, H., Holzer, M., Craxton, M., Emson, P. C., et al. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-21-09340.2002 · Cited by 751
Self-citationFiber diffraction of synthetic α-synuclein filaments shows amyloid-like cross-β conformation
Serpell, L. C., Berriman, J., Jakes, R., Goedert, M., & Crowther, R. A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.9.4897 · Cited by 748
Self-citationOno, K., Yoshiike, Y., Takashima, A., Hasegawa, K., Naiki, H., & Yamada, M. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01976.x · Cited by 681
Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease
Korth, C., May, B. C. H., Cohen, F. E., & Prusiner, S. B. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.161274798 · Cited by 673
Prusiner, S. B. (1991) · PubMed · Cited by 641
Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines.
Wischik, C. M., Edwards, P. C., Lai, R. Y., Roth, M., & Harrington, C. R. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.20.11213 · Cited by 547
Tau proteins with FTDP‐17 mutations have a reduced ability to promote microtubule assembly
Hasegawa, M., Smith, M. J., & Goedert, M. (1998) · FEBS Letters · doi:10.1016/s0014-5793(98)01217-4 · Cited by 483
Self-citationKirschner, D. A., Inouye, H., Duffy, L. K., Sinclair, A., Lind, M., & Selkoe, D. J. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.19.6953 · Cited by 482
The Flavonoid Baicalein Inhibits Fibrillation of α-Synuclein and Disaggregates Existing Fibrils
Zhu, M., Rajamani, S., Kaylor, J., Han, S., Zhou, F., & Fink, A. L. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m403129200 · Cited by 473
Heme oxygenase-1 is associated with the neurofibrillary pathology of Alzheimer's disease.
Smith, M. A., Kutty, R. K., Richey, P. L., Yan, S. D., Stern, D., Chader, G. J., Wiggert, B. O., Petersen, R. B., & Perry, G. L. (1994) · PubMed · Cited by 424
Friedhoff, P., Schneider, A., Mandelkow, E.-M., & Mandelkow, E. (1998) · Biochemistry · doi:10.1021/bi980537d · Cited by 373
Glutamine repeats and neurodegenerative diseases: molecular aspects
Perutz, M. F. (1999) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(98)01350-4 · Cited by 359
Glutamine Repeats and Neurodegenerative Diseases: Molecular Aspects
Suchowersky, O. (2002) · Archives of Neurology · doi:10.1001/archneur.59.6.1038 · Cited by 356
Pickhardt, M., Gazova, Z., von Bergen, M., Khlistunova, I., Wang, Y., Hascher, A., Mandelkow, E.-M., Biernat, J., & Mandelkow, E. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m410984200 · Cited by 333
Doh-ura, K., Iwaki, T., & Caughey, B. (2000) · Journal of Virology · doi:10.1128/jvi.74.10.4894-4897.2000 · Cited by 324
Klunk, W. E., Wang, Y., Huang, G.-F., Debnath, M. L., Holt, D. P., Shao, L., Hamilton, R. L., Ikonomovic, M. D., DeKosky, S. T., & Mathis, C. A. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-06-02086.2003 · Cited by 309
Porphyrin and Phthalocyanine Antiscrapie Compounds
Priola, S. A., Raines, A., & Caughey, W. S. (2000) · Science · doi:10.1126/science.287.5457.1503 · Cited by 302
Berriman, J., Serpell, L. C., Oberg, K. A., Fink, A. L., Goedert, M., & Crowther, R. A. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1530287100 · Cited by 288
Self-citationOno, K., Hasegawa, K., Naiki, H., & Yamada, M. (2004) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2004.06.008 · Cited by 265
Filamentous nerve cell inclusions in neurodegenerative diseases
Goedert, M., Spillantini, M. G., & Davies, S. W. (1998) · Current Opinion in Neurobiology · doi:10.1016/s0959-4388(98)80090-1 · Cited by 262
Self-citationKocisko, D. A., Baron, G. S., Rubenstein, R., Chen, J., Kuizon, S., & Caughey, B. (2003) · Journal of Virology · doi:10.1128/jvi.77.19.10288-10294.2003 · Cited by 231
Heiser, V., Engemann, S., Bröcker, W., Dunkel, I., Boeddrich, A., Waelter, S., Nordhoff, E., Lurz, R., Schugardt, N., Rautenberg, S., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182426599 · Cited by 205
Merlini, G., Ascari, E., Amboldi, N., Bellotti, V, Arbustini, E., Perfetti, V, Ferrari, M., Zorzoli, I., Marinone, M. G., & Garini, P. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.7.2959 · Cited by 205
Approaches to discovery and characterization of inhibitors of amyloid β-peptide polymerization
Findeis, M. A. (2000) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(00)00034-x · Cited by 174
X-ray Diffraction of Scrapie Prion Rods and PrP Peptides
Nguyen, J. T., Inouye, H., Baldwin, M. A., Fletterick, R. J., Cohen, F. E., Prusiner, S. B., & Kirschner, D. A. (1995) · Journal of Molecular Biology · doi:10.1006/jmbi.1995.0507 · Cited by 169
Rifampicin Prevents the Aggregation and Neurotoxicity of Amyloid β Protein in Vitro
Tomiyama, T., Asano, S., Suwa, Y., Morita, T., Kataoka, K., Mori, H., & Endo, N. (1994) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1994.2428 · Cited by 158
Prion diseases — close to effective therapy?
Cashman, N. R., & Caughey, B. W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1525 · Cited by 134
Ligand-Dependent Inhibition and Reversal of Tau Filament Formation
Chirita, C. N., Necula, M., & Kuret, J. (2004) · Biochemistry · doi:10.1021/bi036094h · Cited by 116
Paudel, H. K., & Li, W. S. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.12.8029 · Cited by 106
Hemin and related porphyrins inhibit β‐amyloid aggregation
Howlett, D., Cutler, P., Heales, S., & Camilleri, P. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)01290-8 · Cited by 95
Phthalocyanine Tetrasulfonates Affect the Amyloid Formation and Cytotoxicity of α-Synuclein
Lee, E.-N., Cho, H.-J., Lee, C.-H., Lee, D., Chung, K. C., & Paik, S. R. (2004) · Biochemistry · doi:10.1021/bi0356707 · Cited by 86
Smith, M. J., Crowther, R. A., & Goedert, M. (2000) · FEBS Letters · doi:10.1016/s0014-5793(00)02169-4 · Cited by 49
Self-citationAmphotericin B Binds to Amyloid Fibrils and Delays Their Formation: A Therapeutic Mechanism?
Hartsel, S. C., & Weiland, T. R. (2003) · Biochemistry · doi:10.1021/bi0270384 · Cited by 38
Hall, G. F., Lee, S., & Yao, J. (2002) · Journal of Molecular Neuroscience · doi:10.1385/jmn:19:3:251 · Cited by 34
Inactivation of the Scrapie Agent by Ultraviolet Irradiation in the Presence of Chlorpromazine
Dees, C., Wade, W. F., German, T. L., & Marsh, R. F. (1985) · Journal of General Virology · doi:10.1099/0022-1317-66-4-845 · Cited by 32
Influence of aminasine on experimental scrapie in mice.
Vm, R., Fokina, G. I., & Pogodina, V. V. (1984) · PubMed · Cited by 18
Cited by
Tau-mediated neurodegeneration in Alzheimer’s disease and related disorders
Ballatore, C., Lee, V. M.-Y., & Trojanowski, J. Q. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2194 · Cited by 2,174
Alzheimer Mechanisms and Therapeutic Strategies
Huang, Y., & Mucke, L. (2012) · Cell · doi:10.1016/j.cell.2012.02.040 · Cited by 1,758
Tau pathology and neurodegeneration
Spillantini, M. G., & Goedert, M. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70090-5 · Cited by 1,133
Self-citationProtein drug stability: a formulation challenge
Frokjaer, S., & Otzen, D. E. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1695 · Cited by 1,096
Porat, Y., Abramowitz, A., & Gazit, E. (2006) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2005.00318.x · Cited by 989
Metadata
- Authors
- Taniguchi, S., Suzuki, N., Masuda, M., Hisanaga, S.-I., Iwatsubo, T., Goedert, M., & Hasegawa, M.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2005-03
- Volume
- 280
- Issue
- 9
- Pages
- 7614-7623
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2046436217
- Cited by
- 540
- References
- 53
- FWCI
- 8.74
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.